[ad_1] A probiotic culture experiment in a laboratory. Future Publishing | Future Publishing | Getty Images Seed Health has been in the business of microbiome scientific breakthroughs since its founding in 2015, but its biggest success to-date may have been becoming profitable as a bioscience startup. The popularity of the company’s original product, DS-01, a…
[ad_1] Jonathan Raa | Nurphoto | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Hi folks! Two competing cell therapies from Bristol Myers Squibb and Johnson & Johnson both got good news from the Food and Drug Administration on Friday. But J&J’s drug…
[ad_1] Respiratory syncytial virus – viral vaccine under research Hailshadow | Istock | Getty Images A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are at increased risk of getting severely sick from respiratory syncytial virus in a late stage clinical trial, the company said Tuesday. The initial data…
[ad_1] This story is part of CNBC’s quarterly Cities of Success series, which explores cities that have transformed into business hubs with an entrepreneurial spirit that has attracted capital, companies and employees. The Denver-Boulder region is rapidly emerging as a major hub for the life sciences industry, attracting companies that develop cutting-edge medical treatments and…
[ad_1] The coronal view of a human brain of a patient suffering from Parkinson’s disease Sherbrooke Connectivity Imaging Lab | Getty Images A highly popular class of drugs for diabetes and obesity is showing early potential to help patients with Parkinson’s disease, too. An older diabetes treatment called lixisenatide helped slow the progression of motor…
[ad_1] Daniel Grill | Tetra Images | Getty Images Altimmune on Wednesday said its experimental drug helped patients shed weight but also minimized the loss of muscle mass in a midstage trial, a finding that could set it apart in a potentially crowded market. Altimmune is one of several smaller biotech companies that are pushing…
[ad_1] A box of Ozempic and contents sit on a table in Dudley, North Tyneside, Britain, October 31, 2023. Lee Smith | Reuters The blockbuster diabetes drug Ozempic could be manufactured for less than $5 a month, even as Novo Nordisk charges close to $1,000 per month for the injection in the U.S. before insurance,…
[ad_1] Nikos Pekiaridis | Lightrocket | Getty Images Moderna has more to offer beyond its Covid vaccine. The biotech company made that clear on Wednesday, announcing positive clinical trial data on three experimental vaccines for other diseases. The company is moving those shots to final stage studies, it said. The update brings Moderna a step…
[ad_1] The Food and Drug Administration on Tuesday approved a drug from Merck designed to treat a progressive and life-threatening lung condition in a win for both the drugmaker and for patients suffering from the rare disease. The agency greenlighted the therapy, which will be marketed as Winrevair, for adults with pulmonary arterial hypertension. The…
[ad_1] Alexey Krukovsky | Istock | Getty Images Viking Therapeutics shares closed more than 15% higher on Tuesday after the company said its experimental weight loss pill showed positive results in a small study and will enter the next stage of development later this year. The study results add to the excitement around the drugmaker’s…
